Inclusion body myositis: New insights into pathogenesis

Current Opinion in Rheumatology

Volumn 20, Issue 6, 2008, Pages 662-668

  Garlepp, Michael J ^a,c   Mastaglia, Frank L ^b  

^a CURTIN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

amyloid; Autoimmunity; E3 ligase; Inclusion body myositis; Myostatin

Indexed keywords

AMYLOID BETA PROTEIN; CHEMOKINE RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN PROTEIN LIGASE E3;

AUTOIMMUNITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE COURSE; GENETIC ASSOCIATION; HUMAN; HUMORAL IMMUNITY; INCLUSION BODY MYOSITIS; MUSCLE REGENERATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; T LYMPHOCYTE;

AMYLOID BETA-PROTEIN; ANIMALS; AUTOIMMUNITY; B-LYMPHOCYTES; CYTOKINES; HUMANS; MICE; MUSCLE PROTEINS; MYOSITIS, INCLUSION BODY; REGENERATION; T-LYMPHOCYTES;

EID: 56249083915     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328313644c     Document Type: Review

References (51)

1. Needham M, Mastaglia FL. Sporadic inclusion body myositis: a continuing puzzle. Neuromuscul Disord 2008; 18:6-16.
2. Needham M, James I, Corbett A, et al. Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry 2008; 79:1056-1060.
3. Dalakas MC. Sporadic inclusion body myositis: diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol 2006; 2:437-447.
4. Oldfors A, Moslemi AR, Jonasson L, et al. Mitochondrial abnormalities in inclusion-body myositis. Neurology 2006; 66:S49-S55.
5. Kannanayakal TJ, Mendell JR, Kuret J. Casein kinase 1 alpha associates with tau-bearing lesions of inclusion body myositis. Neurosci Lett 2008; 431: 141-145.
6. Price P, Santoso L, Mastaglia F, et al. Two major histocompatibility complex haplotypes influence susceptibility to sporadic inclusion body myositis: critical evaluation of an association with HLA-DR3. Tissue Antigens 2004; 64:575-580.
7. Barohn RJ, Amato AA, Sahenk Z, et al. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology 1995; 45:1302-1304.
8. Argov Z, Eisenberg I, Grabov-Nardini G, et al. Hereditary inclusion body myopathy: the Middle Eastern genetic cluster. Neurology 2003; 60:1519-1523.
9. Argov Z, Mitrani-Rosenbaum S. Hereditary inclusion body myopathy and other rimmed vacuolar myopathies. In: Mastaglia FL, Hilton-Jones DJ, editors. Clinical handbook of neurology. Vol 86. Elsevier 2007; pp. 243-253.
10. Ricci E, Broccolini A, Gldaro T, et al. NCAM is hyposialylated in hereditary inclusion body myopathy due to GNE mutations. Neurology 2006; 66:755-758.
11. Krause S, Schlotter-Weigel B, Walter M, et al. A novel homozygous missense mutation in the GNE gene of a patient with quadriceps-sparing hereditary inclusion body myopathy associated with muscle inflammation. Neuromusoul Disord 2003; 13:830-834.
12. Vasconcelos OM, Raju R, Dalakas M. GNE mutations in an American family with quadriceps-sparing IBM and lack of mutations in s-IBM. Neurology 2002; 59:1776-1779.
13. Tajsharghi H, Thornell LE, Darin N, et al. Myosin heavy chain IIa gene mutation E706K is pathogenic and its expression increases with age. Neurology 2002; 58:780-786.
14. Watts GDJ, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004; 36:377-381.
15. Haubenberger D, Bittner RE, Rauch-Shorny S, et al. Inclusion body myopathy and Paget disease is linked to a novel mutation in VCP gene. Neurology 2005; 65:1304-1305.
16. Weihl CC, Miller SE, Hanson PI, Pestronk A. Transgenic expression of inclusion body myopathy associated mutant p97/VCP causes weakness and ubiquitinated protein inclusions in mice. Hum Mol Genet 2007; 16: 919-928. Demonstration that intramuscular expression of mutant VCP results in accumulation of ubiquinated proteins and reproduction of many of the pathological aspects of IBM.
17. Ikezoe K, Ohshima S, Osegawa M, et al. Expression of granulysin in polymyositis and inclusion body myositis. J Neurol Neurosurg Psychiatry 2006; 77:1104-1105.
18. Grundtman C, Malmstrom V, Lundberg IE. Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies. Arthritis Res Ther 2007; 9:208. doi:10.1186/ar2139.
19. Schmidt J, Rakocevic G, Raju R, et al. Up-regulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity. Brain 2004; 127:1182-1190.
20. Garlepp MJ, Chen W, Tabarias H, et al. Antigen processing and presentation by a murine myoblast cell line. Clin Exp Immunol 1995; 102:614-619.
21. Shirota H, Petrenko L, Hong C, Klinman DM. Potential of transfected muscle cells to contribute to DNA vaccine immunogenicity. J Immunol 2007; 179: 329-336.
22. Lunemann JD, Schmidt J, Schmid D, Barthel K, et al. Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis. Autophagy 2007; 3:384-386.
23. Greenberg SA, Pinkus GS, Amato AA, Pinkus JL. Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve 2007; 35:17-23. The demonstration of potent antigen presenting cells in very intimate contact with myofibres and inflammatory T cells in s-IBM making an argument for intramuscular autoantigen presentation.
24. Salajegheh M, Rakocevic G, Raju R, et al. T cell receptor profiling in muscle and blood lymphocytes in sporadic inclusion body myositis. Neurology 2007; 69:1672-1679. Demonstration of limited intramuscular 143 gene usage and epitope spreading suggesting an intramuscular autoantigen-specific immune response.
25. Greenberg SA, Bradshaw EM, Pinkus JL, et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 2005; 65:1782-1787.
26. Bradshaw EM, Otihueta A, McArdel S, et al. A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol 2007; 178:547-556.
27. Arnett HA, Escobar SS, Gonsalez-Suarez E, et al. BTLN2, a butyrophilin/B7-like molecule, is a negative co-stimulatory molecule modulated in intestinal inflammation. J Immunol 2007; 178:1523-1533.
28. Valentonyte R, Hampe J, Huse K, et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet 2005; 37:357-364.
29. De Paepe B, Creus KK, De Bleeker JL. Chemokine profiles of different inflammatory myopathies reflects humoral versus cytotoxic immune responses. Ann N Y Acad Sci 2007; 1109:441-453.
30. Schmidt J, Barthel K, Wrede A, et al. Interrelation of inflammation and APP in sIBM: IL-1β induces accumulation of β-amyloid in skeletal muscle. Brain 2008; 131:1228-1240. Provides data correlating cytokine expression with APP expression in s-IBM. Degeneration markers and APP are expressed in polymyositis and dermatomyositis but differ in the intramuscular distribution to s-IBM.
31. 42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice. Am J Pathol 2006; 168: 1986-1997.
32. Kitazawa M, Trinh DN, LaFerla FM. Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3β. Annal Neurol 2008;64:15-24. Provides data linking inflammation and IL-1β to hyperphosphorylation of tau, via GSK-3β, and β-amyloid accumulation.
33. Askanas V, Engel WK. Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis. Curr Opin Rheumatol 2007; 19:550-559.
34. Yoshida H. ER stress and diseases. FEBS J 2007; 274:630-658.
35. Delaunay A, Bromberg KD, Hayashi Y, et al. The ER-Bound RING finger protein 5 (RNF5/RMA1) causes degenerative myopathy in transgenic mice and is deregulated in inclusion body myositis. Plos ONE 2008; 3:e1609. doi:10.1371/journal.pone.0001609. A transgenic model of RNF5 illustrating that overexpression of an E3 ligase can generate a myopathy characterized by muscle wasting and degeneration, congophilic material and endoplasmic reticulum stress markers.
36. Rosen KM, Veereshwarayya V, Moussa CE-H, et al. Parkin protects against mitochondrial toxins and beta-amyloid accumulation in skeletal muscle cells. J Biol Chem 2006; 281:12809-12816.
37. Luneman JD, Schmidt J, Dalakas MC, Munz C. Macroautophagy as a pathomechanism in sporadic inclusion body myositis. Ann Neurol 2007; 61:476-483.
38. Fratta P, Engel WK, Mcferrin J, et al. Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-over-expressing cultured human muscle fibers. Am J Pathol 2005; 167:517-526.
39. Banwell BL, Engel AG. αB-crystallin immunolocalisation yields new insights into inclusion body myositis. Neurology 2000; 14:1033-1041.
40. Wojcik S, Engel WK, MoFerrin J, et al. AβPP over-expression and proteosome inhibition increase αB-crystallin in cultured human muscle: relevance to inclusion body myositis. Neuromuscul Disord 2006; 16:839-844.
41. Wojcik S, Engel WK, Riqiang Y, et al. NOGO is increased and binds to BACE1 in sporadic inclusion-body myositis and in AβPP-over-expressing cultured human muscle fibers. Acta Neuropathol 2007; 114:517-526.
42. Eisenberg I, Eran A, Nishino I, et al. Distinctive patterns of microRNA expression in primary muscular disorders. Proc Natl Acad Sci U S A 2007; 104:17016-17021.
43. Nagaraju K, Raben N, Loeffler L, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci U S A 2000; 97:9209-9214.
44. Nagaraju K, Casciola-Rosen L, Lundberg I, et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis. Arthritis Rheum 2005; 52:1824-1835.
45. Pavlath GK. Regulation of class I MHC expression in skeletal muscle: deleterious effect of aberrant expression on myogenesis. J Neuroimmunol 2002; 125:42-50.
46. Wojcik S, Engel WK, McFerrin J, Askanas V. Myostatin is increased and complexes with amyloid-beta within sporadic inclusion body myositis muscle fibers. Acta Neuropathol (Berl) 2005; 110:173-177.
47. Nogalska A, Wojcik W, Engel WK, et al. Endoplasmic reticulum stress induces myostatin precursor protein and NF-kB in cultured human muscle fibers: relevance to inclusion body myositis. Exp Neurol 2007; 204:610-618. Provides data confirming the relationship between endoplasmic reticulum stress and MPP expression in muscle and a possible link to muscle atrophy in s-IBM.
48. Wojcik S, Nogalska A, McFerrin J, et al. Myostatin precursor protein is increased and associates with amyloid-β precursor protein in inclusion-body myositis culture model. Neuropathol Appl Neurobiol 2007; 33:238-242. Evidence of link between APP overexpression and MPP accumulation.
49. Tang L, Yan Z, Wan Y, et al. Myostatin DNA vaccine increases skeletal muscle mass and endurance in mice. Muscle Nerve 2007; 36:342-348. Vaccination against myostatin by intramuscular inoculation of naked DNA expressing a myostatin epitope enhances muscle growth and function in a murine model.
50. Morosetti R, Mirabella M, Gliubizzi C, et al. MyoD expression restores defective myogenic differentiation of human mesangioblasts from inclusion-body myositis muscle. Proc Natl Acad Sci U S A 2006; 103:16995-17000.
51. Coletti D, Yang E, Marazzi G, Sassoon D. TNFα inhibits skeletal myogenesis through a PW1-dependent pathway by recruitment of caspase pathways. EMBO J 2002; 21:631-642.